In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In mid-December 2025, an image (archived) circulated online purportedly showing U.S. President Donald Trump using a walker as a mobility aid. Keith Edwards, a Democratic political strategist, posted ...

The way you endorse a check depends on how you want to use the check Kiara Taylor has worked as a financial analyst for more than a decade. Her career has involved a number of financial firms, ...

Toni is a points and miles enthusiast who has been leveraging loyalty programs to travel around the world (for nearly free) with her husband and their four young children. She’s passionate about ...

Notable: Seattle is up to 54% to earn the No. 1 seed after beating the Panthers on Sunday, according to The Athletic's playoff predictor. If they beat the Niners on Saturday night, they'll win the No.